RENAL-SHIELD: Kidney Protection in Diabetic Nephropathy

A study of an SGLT2 inhibitor combination for slowing kidney function decline in patients with type 2 diabetes and early chronic kidney disease.

Key eligibility criteria

• Adults 30–80 years
• T2D with eGFR 30–75
• UACR 200–5000 mg/g
• On stable ACE/ARB therapy

Additional criteria apply. A full eligibility review is completed by our coordinators during pre-screening — you may still qualify even if you're unsure about a criterion.